Assembly Free Cash Flow vs Stock Based Compensation Analysis
ASMB Stock | USD 16.11 0.59 3.53% |
Assembly Biosciences financial indicator trend analysis is way more than just evaluating Assembly Biosciences prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Assembly Biosciences is a good investment. Please check the relationship between Assembly Biosciences Free Cash Flow and its Stock Based Compensation accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Assembly Biosciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population. For information on how to trade Assembly Stock refer to our How to Trade Assembly Stock guide.
Free Cash Flow vs Stock Based Compensation
Free Cash Flow vs Stock Based Compensation Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Assembly Biosciences Free Cash Flow account and Stock Based Compensation. At this time, the significance of the direction appears to have significant contrarian relationship.
The correlation between Assembly Biosciences' Free Cash Flow and Stock Based Compensation is -0.44. Overlapping area represents the amount of variation of Free Cash Flow that can explain the historical movement of Stock Based Compensation in the same time period over historical financial statements of Assembly Biosciences, assuming nothing else is changed. The correlation between historical values of Assembly Biosciences' Free Cash Flow and Stock Based Compensation is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Free Cash Flow of Assembly Biosciences are associated (or correlated) with its Stock Based Compensation. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Stock Based Compensation has no effect on the direction of Free Cash Flow i.e., Assembly Biosciences' Free Cash Flow and Stock Based Compensation go up and down completely randomly.
Correlation Coefficient | -0.44 |
Relationship Direction | Negative |
Relationship Strength | Very Weak |
Free Cash Flow
The amount of cash a company generates after accounting for cash outflows to support operations and maintain its capital assets.Stock Based Compensation
Compensation provided to employees in the form of equity or options to purchase company stock. This type of compensation is used to align the interests of employees and shareholders.Most indicators from Assembly Biosciences' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Assembly Biosciences current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Assembly Biosciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population. For information on how to trade Assembly Stock refer to our How to Trade Assembly Stock guide.The current year's Tax Provision is expected to grow to about 34.6 K, whereas Selling General Administrative is forecasted to decline to about 17.7 M.
2021 | 2022 | 2023 | 2024 (projected) | Interest Income | 302K | 1.0M | 2.4M | 1.6M | Net Interest Income | 302K | 1.0M | 2.4M | 1.6M |
Assembly Biosciences fundamental ratios Correlations
Click cells to compare fundamentals
Assembly Biosciences Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Assembly Biosciences fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 339.9M | 283.3M | 191.1M | 101.8M | 136.8M | 130.2M | |
Other Current Liab | 13.1M | 13.0M | 7.1M | 7.1M | 6.6M | 5.0M | |
Total Current Liabilities | 24.4M | 24.4M | 16.1M | 16.3M | 39.2M | 41.2M | |
Total Stockholder Equity | 273.2M | 240.6M | 168.9M | 82.7M | 41.1M | 39.0M | |
Property Plant And Equipment Net | 13.8M | 10.7M | 7.2M | 3.9M | 2.7M | 3.0M | |
Net Debt | (34.5M) | (49.3M) | (39.2M) | (49.0M) | (17.5M) | (18.4M) | |
Retained Earnings | (439.4M) | (501.6M) | (631.4M) | (724.5M) | (785.7M) | (746.5M) | |
Accounts Payable | 1.7M | 4.6M | 2.7M | 2.5M | 461K | 438.0K | |
Cash | 46.7M | 59.4M | 45.6M | 52.4M | 19.8M | 36.5M | |
Non Current Assets Total | 57.1M | 58.8M | 36.9M | 4.8M | 3.0M | 2.9M | |
Non Currrent Assets Other | 1.7M | 6.4M | 1.7M | 78K | 312K | 296.4K | |
Other Assets | 1.7M | 6.4M | 1.7M | (646.0K) | (742.9K) | (705.8K) | |
Cash And Short Term Investments | 274.0M | 216.4M | 146.6M | 91.6M | 130.2M | 99.4M | |
Common Stock Total Equity | 25K | 32K | 34K | 49K | 56.4K | 59.2K | |
Common Stock Shares Outstanding | 2.2M | 39.7M | 46.8M | 4.0M | 4.6M | 4.3M | |
Liabilities And Stockholders Equity | 339.9M | 283.3M | 191.1M | 101.8M | 136.8M | 130.2M | |
Non Current Liabilities Total | 42.3M | 18.2M | 6.1M | 2.8M | 56.5M | 62.5M | |
Other Current Assets | 5.4M | 13.7M | 14.5M | 4.4M | 300K | 285K | |
Other Stockholder Equity | 712.8M | 742.4M | 800.7M | 807.9M | 826.9M | 868.3M | |
Total Liab | 66.7M | 42.7M | 22.1M | 19.1M | 95.7M | 100.5M | |
Property Plant And Equipment Gross | 13.8M | 10.7M | 7.2M | 3.9M | 2.9M | 3.0M | |
Total Current Assets | 282.8M | 224.5M | 154.2M | 97.0M | 133.8M | 102.4M | |
Accumulated Other Comprehensive Income | (201K) | (270K) | (419K) | (803K) | (81K) | (85.1K) | |
Common Stock | 32K | 34K | 48K | 49K | 5K | 4.8K | |
Property Plant Equipment | 1.8M | 1.6M | 7.2M | 743K | 854.5K | 1.0M | |
Net Tangible Assets | 231.6M | 198.9M | 168.9M | 82.7M | 95.1M | 107.5M | |
Retained Earnings Total Equity | (341.8M) | (439.4M) | (501.6M) | (724.5M) | (652.1M) | (619.5M) | |
Short Term Investments | 227.3M | 157.0M | 101M | 39.2M | 110.4M | 77.4M | |
Capital Surpluse | 552.8M | 712.8M | 742.4M | 807.9M | 929.1M | 975.6M | |
Other Liab | 38.9M | 33.2M | 11.5M | 2.7M | 2.5M | 2.3M | |
Current Deferred Revenue | 5.1M | 6.4M | 9.0M | 2.7M | 30.9M | 32.5M | |
Net Receivables | 3.4M | 1.2M | 336K | 944K | 43K | 40.9K | |
Net Invested Capital | 273.2M | 240.6M | 168.9M | 82.7M | 41.1M | 39.0M | |
Net Working Capital | 258.3M | 200.1M | 138.1M | 80.7M | 94.6M | 124.0M | |
Capital Stock | 32K | 34K | 48K | 49K | 5K | 4.8K |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Assembly Biosciences offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Assembly Biosciences' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Assembly Biosciences Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Assembly Biosciences Stock:Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Assembly Biosciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population. For information on how to trade Assembly Stock refer to our How to Trade Assembly Stock guide.You can also try the Sign In To Macroaxis module to sign in to explore Macroaxis' wealth optimization platform and fintech modules.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Assembly Biosciences. If investors know Assembly will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Assembly Biosciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (6.89) | Revenue Per Share 4.125 | Quarterly Revenue Growth (1.00) | Return On Assets (0.35) | Return On Equity (1.02) |
The market value of Assembly Biosciences is measured differently than its book value, which is the value of Assembly that is recorded on the company's balance sheet. Investors also form their own opinion of Assembly Biosciences' value that differs from its market value or its book value, called intrinsic value, which is Assembly Biosciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Assembly Biosciences' market value can be influenced by many factors that don't directly affect Assembly Biosciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Assembly Biosciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Assembly Biosciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Assembly Biosciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.